Molecular genotyping in medullary thyroid cancer

被引：2
|
作者：
Newbold, Kate [1 ,2 ]
机构：
[1] Royal Marsden NHS Fdn Trust Hosp, London, England
[2] Royal Marsden NHS Fdn Trust Hosp, Consultant Clin Oncologist, Fulham Rd, London SW3 6JJ, England
来源：
CURRENT OPINION IN ONCOLOGY | 2023年 / 35卷 / 01期
关键词：
medullary thyroid cancer; rearranged during transfection; ACQUIRED-RESISTANCE; RET PROTOONCOGENE; RAS MUTATIONS; CARCINOMA; ACTIVATION; SELPERCATINIB; CABOZANTINIB;
D O I：
10.1097/CCO.0000000000000915
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose of reviewThere has been a significant advance in our understanding of the molecular biology of medullary thyroid cancer (MTC) alongside progress in the development of targeted therapies including multikinase and specific rearranged during transfection inhibitors.Recent findingsThis review will examine the latest data investigating the impact of the genomics of MTC on the prediction of the natural history of an individual's disease and the determination, selection and timing of treatment interventions.Recent advances in genotyping in MTC and the development of targeted therapies have impacted on the clinical management of both sporadic and hereditary MTC.
引用
收藏
页码：10 / 14
页数：5
相关论文
共 50 条
  • [21] Medullary Thyroid Cancer: New Targeted Molecular Therapies
    Antonelli, Alessandro
    Ferrari, Silvia Martina
    Fallahi, Poupak
    Minuto, Michele
    Corrado, Alda
    Bruno, Rossella
    Miccoli, Paolo
    RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY, 2010, 4 (01) : 10 - 14
  • [22] The role of molecular genetics in the clinical management of sporadic medullary thyroid carcinoma: A systematic review
    Fussey, Jonathan Mark
    Vaidya, Bijay
    Kim, Dae
    Clark, Jonathan
    Ellard, Sian
    Smith, Joel Anthony
    CLINICAL ENDOCRINOLOGY, 2019, 91 (06) : 697 - 707
  • [23] Medullary thyroid cancer: molecular factors, management and treatment
    Pavlidis, Efstathios
    Sapalidis, Konstantinos
    Chatzinikolaou, Fotios
    Kesisoglou, Isaak
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2020, 61 (03) : 681 - 686
  • [24] Cabozantinib for progressive metastatic medullary thyroid cancer: a review
    Colombo, Joshua R.
    Wein, Richard O.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2014, 10 : 395 - 404
  • [25] New drugs for medullary thyroid cancer: new promises?
    Spitzweg, Christine
    Morris, John C.
    Bible, Keith C.
    ENDOCRINE-RELATED CANCER, 2016, 23 (06) : R287 - R297
  • [26] Surgical aspects and controversies in the management of medullary thyroid cancer
    Green, Katerina
    Hintze, Justin
    O'Neill, James Paul
    IRISH JOURNAL OF MEDICAL SCIENCE, 2022, 191 (06) : 2461 - 2466
  • [27] PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy
    Manfredi, Gloria Irene
    Dicitore, Alessandra
    Gaudenzi, Germano
    Caraglia, Michele
    Persani, Luca
    Vitale, Giovanni
    ENDOCRINE, 2015, 48 (02) : 363 - 370
  • [28] Current status of the prognostic molecular markers in medullary thyroid carcinoma
    Oczko-Wojciechowska, Malgorzata
    Czarniecka, Agnieszka
    Gawlik, Tomasz
    Jarzab, Barbara
    Krajewska, Jolanta
    ENDOCRINE CONNECTIONS, 2020, 9 (12): : R251 - R263
  • [29] Aggressive medullary thyroid cancer, an analysis of the Irish National Cancer Registry
    Lennon, P.
    Deady, S.
    White, N.
    Lambert, D.
    Healy, M. L.
    Green, A.
    Kinsella, J.
    Timon, C.
    O'Neill, J. P.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 (01) : 89 - 95
  • [30] Medullary Thyroid Cancer: Updates and Challenges
    Gild, Matti L.
    Clifton-Bligh, Roderick J.
    Wirth, Lori J.
    Robinson, Bruce G.
    ENDOCRINE REVIEWS, 2023, 44 (05) : 934 - 946
12345